Tinuviel Therapeutics Announces Collaboration with Hudson Institute of Medical Research

22 Jun, 2026

Tinuviel Therapeutics and Hudson Institute of Medical Research are combining experimental microbiome science with AI-powered digital-twin modeling to predict microbiome resilience and accelerate precision diagnostics and therapeutics.

Tinuviel Therapeutics and Hudson Institute of Medical Research are partnering through Wellcome Leap’s FORM program to bridge world-class experimental microbiome science with advanced computational biology. By combining Hudson’s expertise in microbial culturing, systems biology, and translational microbiome research with Tinuviel’s capabilities in artificial intelligence and digital-twin modeling, the collaboration is creating a closed-loop experimental-computational platform to measure, model, and predict human microbiome resilience, opening new pathways for precision diagnostics, predictive medicine, and therapeutic design.

More News

29 Jun, 2026

Tinuviel Therapeutics Partners with Kipu Quantum to Combat Drug-Resistant Infections

Tinuviel Therapeutics and Kipu Quantum are applying quantum-enhanced computational methods to model complex microbial ecosystems and identify new strategies for treating drug-resistant infections.

15 Jun, 2026

Tinuviel Therapeutics is Selected for the Wellcome Leap FORM Program

Supported by Wellcome Leap's $50M FORM program, Tinuviel Therapeutics is combining AI, systems biology, and microbiome science to build predictive tools for early-life health and next-generation therapeutics.

24 Apr, 2026

Tinuviel Therapeutics Announces Collaboration with JIJ to Advance Predictive Microbiome Modeling

Tinuviel Therapeutics and JIJ are partnering to integrate mathematical optimization, advanced computing, and digital-twin modeling, moving microbiome research from description to prediction.